The 13D proxy action is to benefit new large investors who will buy shares in a secondary and will be allowed to short sell CYDY with a prior agreement to be allocated shares in the secondary offering possibly with warrants at a below market price. It happens very frequently in pre-revenue biotech and is legal to do. Easy pickings from retail, they will without a doubt legally rob current retail investors in this manner. <br /> Your bear thesis opinions are water under the bridge at this point. The 13 D group poses a clear danger of current shareholders being legally robbed in a dilutive secondary stock offering.